Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Findings likely to generate hypotheses about potential new uses of drugs
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
The company uses iPS cells to develop treatments for diseases relating to the kidney
Subscribe To Our Newsletter & Stay Updated
